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Abstract: Although the observation of aerobic glycolysis of tumor cells by Otto v. Warburg had demonstrated abnormali-
ties of mitochondrial energy metabolism in cancer decades ago, there was no clear evidence for a functional role of mutant 
mitochondrial proteins in cancer development until the early years of the 21
st century. In the year 2000, a major break-
through was achieved by the observation, that several genes coding for subunits of the respiratory chain (ETC) complex 
II, succinate dehydrogenase (SDH) are tumor suppressor genes in heritable paragangliomas, fulfilling Knudson’s classical 
two-hit hypothesis. A functional inactivation of both alleles by germline mutations and chromosomal losses in the tumor 
tissue was found in the patients. Later, SDH mutations were also identified in sporadic paragangliomas and pheochromo-
cytomas. Genes of the mitochondrial ATP-synthase and of mitochondrial iron homeostasis have been implicated in cancer 
development at the level of cell culture and mouse experiments. In contrast to the well established role of some nuclear 
SDH genes, a functional impact of the mitochondrial genome itself (mtDNA) in cancer development remains unclear. 
Nevertheless, the extremely high frequency of mtDNA mutations in solid tumors raises the question, whether this small 
circular genome might be applicable to early cancer detection. This is a meaningful approach, especially in cancers, which 
tend to spread tumor cells early into bodily fluids or faeces, which can be screened by non-invasive methods. 
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1. INTRODUCTION: ENERGY METABOLISM OF 
CANCER CELLS  
1.1. Otto Warburg’s Unproven Hypothesis 
  More than eighty years ago, Otto Heinrich Warburg be-
gan his pioneering work on tumor cell metabolism, which 
culminated in the hypothesis that endogenous respiration 
defects of cancer cells, accompanied by the slow develop-
ment of an enhanced ‘aerobic glycolysis’ during carcino-
genesis,` would be a metabolic switch, actually defining the 
root of cancer [1,2]. This metabolic cancer hypothesis in its 
strict sense has largely been forgotten, since the era of ge-
netic carcinogenesis concepts revolutionized science. Al-
though changes in energy metabolism today are not regarded 
to be the cause of cancer, the idea of enhanced aerobic gly-
colysis (‘Warburg effect’), being a general metabolic foot-
print of cancer, is still present in the literature. It is even used 
as a rational for the clearly effective metabolic PET imaging 
(
18F-deoxy-glucose positron emission  tomography) of solid 
tumors, which exploits the increased accumulation of a la-
beled glucose-derivative in the tumor tissue, since enhanced 
glycolytic flux would require enhanced glucose uptake. 
However, the stimulation of glycolytic flux can be explained 
more easily by the common and often very pronounced hy-
poxia of solid tumors. Other molecular alterations may play 
an additional role for deoxy-glucose enrichment, such as 
increased activity of the glucose carrier Glut-1 [3,4]. Instead 
of using imported glucose mainly glycolytically, some tu-
mors may convert it into fatty acids, since they contain in-
creased amounts of fatty acid synthase [5].  
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  The first one to criticize Warburg’s concept was Wein-
house [6], who already mentioned in the year 1956 that some 
normal tissues, such as brain, retina, intestinal mucosa, and 
kidney medulla, exhibit similar aerobic lactate production as 
compared with Warburg’s model, i.e. ascites tumor cells. 
Moreover, he stated that several tumor cells show rates of 
complete glucose and fatty acid oxidation, which were quite 
similar to normal cells. Remarkably, this topic remained a 
matter of debate until now. Warburg had noticed that ascites 
tumor cells under normoxic conditions gain roughly half of 
their ATP demand by fermentation of glucose to the end 
product lactate, while the glycolytic ATP contribution of 
adult mouse liver and kidney is less than 1% [7]. While the 
observation of a high glycolytic ATP contribution under 
normoxia applies also to several other tumor cells in culture, 
it does not apply generally to all tumor cell lines, in which 
both, glycolytic and oxidative ATP contributions, had been 
precisely measured (for review see [7]). Vice versa, some 
normal tissues exhibit a high contribution of aerobic glycoly-
sis to fulfill their energy demands [7]. No statistically sig-
nificant difference was observed between the groups of nor-
mal and tumor cells, if a meta-analysis of the literature was 
performed, which included only publications, in which both 
ATP generating pathways were measured in parallel. 
1.2. Hexokinase II, a Molecular Link to the ‘Warburg 
Effect’  
  Although ‘enhanced aerobic glycolysis’ is far away from 
being a general and specific feature of cancer cells, molecu-
lar alterations exist in some cancers, which support a ‘War-
burg effect’. The best studied among them is a switch in 
hexokinase  (HK) isoenzymes during tumor development. 
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glycolytic pathway, the ATP-consuming phosphorylation of 
glucose to glucose-6-phosphate (G-6-P). Although glycolysis 
takes place in the cytoplasm, since 1959 some authors had 
described in various articles that a fraction of hexokinase 
activity of tumor cells appeared in a particulate cell fraction, 
which already pointed towards a mitochondrial association. 
In 1977, Bustamante and Pederson found a 20-fold increase 
of hexokinase activity in the azo-dye-derived rat hepatoma 
line H-91 as compared to normal or regenerating rat liver [8]. 
The enzyme was not significantly inhibited by low concen-
trations (< 0.6 mM) of its reaction product G-6-P in contrast 
to results reported earlier from brain hexokinase. Half of the 
activity was found in the mitochondrial cell fraction and the 
enzyme seemed to be coupled directly to the oxidative phos-
phorylation (OXPHOS), i.e. to the oxidative mitochondrial 
pathway of ATP synthesis.  
  Meanwhile, many more molecular details of this relation-
ship have been elucidated (for review see [9]). Among the 
four known human isoenzymes, mainly HK II and to lesser 
degree HK I are upregulated in several human cancers, while 
the low affinity isoform HK IV is silenced [10-12]. This 
isoenzyme switch could be followed in detail during liver 
carcinogenesis. In contrast, most normal tissues express only 
little HK II [13, 14]. The HK II gene promoter was found to 
be inactivated by methylation in normal hepatocytes, while 
this methylation was lost in hepatoma cells during carcino-
genesis [15]. The results indicated that epigenetic changes 
during transformation or tumor progression may underlie the 
isoenzyme switch. However, also a low-grade intra-
chromosomal amplification of the HK II gene had been ob-
served during hepato-carcinogenesis [16]. Both mechanisms 
may participate in the 100-fold increase in HK II mRNAs 
observed in northern blots [17-19].  
  A molecular basis for the suggested relationship between 
OXPHOS and HK II [8] was found in the discovery of a 
physical interaction of HK II with a pore-forming protein in 
the outer mitochondrial membrane, the voltage dependent 
anion channel (VDAC) [20]. ATP generated during OX-
PHOS in the mitochondrial matrix is transported via ANT 
(adenosine nucleotide translocator) through the inner mito-
chondrial membrane and leaves the mitochondria towards 
the cytoplasm via VDAC. In the HK II overexpressing tumor 
cells, ATP is, thus, directly channeled to the enzyme [21]. In 
this way, oxidatively generated ATP can be utilized to stimu-
late phosphorylation of glucose to G-6-P in the cytoplasm. 
The high abundance and high activity (decreased product 
inhibition) of the HK II hexokinase isoform in the tumor 
cells may be an important trigger of enhanced glucose utili-
zation and lactate production of tumor cells even under nor-
moxic conditions, under which mitochondrial ATP is avail-
able as an additional fuel of the hexokinase reaction. Besides 
these metabolic considerations, another role of HK II in cre-
ating a more malignant phenotype may be discussed, since 
VDAC is an essential component of the mitochondrial per-
meability transition pore (mPTP). Since the mPTP is sug-
gested to be a major player in the intrinsic, mitochondrial 
pathway of apoptosis, a binding partner of VDAC may be 
involved in apoptosis resistance. This could be demonstrated 
by some authors [22, 23], while disruption of the HKII-
VDAC-interaction enhanced apoptosis induction [24].  
1.3. VHL-Gene Inactivation Mimics Hypoxia and In-
duces Cancer: A Second Link to Warburg 
  Despite induction of neoangiogenesis, hypoxia is a com-
mon phenomenon in solid tumors, to which tumor cells have 
to adapt their energy metabolism in order to survive and to 
further allow cell proliferation. This requires enhanced glu-
cose uptake and glycolysis, since ATP cannot be delivered 
by the generally more efficient OXPHOS in the absence of 
O2. It is, therefore, not surprising that the expression of Glut-
1 and at least one isoform of all glycolytic enzymes are in-
creased during the HIF-1 (hypoxia inducible factor 1)- medi-
ated hypoxia response. The -subunit of the heterodimeric 
transcription factor HIF-1 is instable under normoxic condi-
tions, since an O2-requiring hydroxylation of two prolyl resi-
dues is the prerequisite for the recognition of the -subunit 
by the E3-ubiquitin ligase complex, which initiates degrada-
tion of the protein. Hypoxia thus stabilizes the protein and 
allows the building of sufficient amounts of active heterodi-
meric HIF-1, which targets many known hypoxia response 
genes, Glut-1 and glycolytic enzymes being among them.  
 Inactivation  of  the  von-Hippel-Lindau  (VHL)- tumor 
suppressor gene is a well-studied example of a pseudo-
hypoxia reaction increasing glycolytic flux via HIF-1 in tu-
mor cells [25]. The biallelic loss of this tumor suppressor 
gene is known to predispose patients to various benign and 
malignant neoplasms, mainly retinal, cerebellar and spinal 
hemangioblastomas, but also renal cell carcinoma, pheocro-
mocytoma, and pancreatic cancer [26, 27]. The protein of the 
VHL gene (pVHL) is a subunit of the E3-ubiquitine ligase 
complex, which binds ubiquitin to all three isoforms of HIF-
1. A loss of pVHL-function therefore leads to HIF-1 stabi-
lization, followed by a chain of events, which would nor-
mally be elicited by hypoxia. VHL inactivation by germ line 
mutation and loss of heterozygosity (LOH) is, therefore, a 
second, although rare, molecular alteration in tumors, which 
enables a ‘Warburg effect’. The glycolytic product pyruvate 
would normally enter the Krebs cycle via pyruvate dehydro-
genase (PDH). Since the PDH-phosphorylating (inhibiting) 
enzyme pyruvate dehydrogenase kinase 1 (PDK1) is among 
the HIF-1 targets, VHL-inactivation at the same time inhibits 
Krebs cycle and OXPHOS. As a consequence, most of the 
pyruvate has to be metabolized to lactate. Taken together, 
this represents a switch from oxidative to glycolytic ATP 
generation under normoxia. In the following paragraph, it 
will be shown that the chain of events eliciting a pseudo-
hypoxia response can also have its primary origin in a mito-
chondrial dysfunction. The inhibition of two Krebs cycle 
enzymes by gene mutation can induce tumor growth, which 
means that enzymes of the oxidative energy metabolism act 
as true tumor suppressors at least in some relatively rare tu-
mor diseases.  
2. ENZYMES OF THE KREBS CYCLE AS TUMOR 
SUPPRESSORS 
2.1. Succinate dehydrogenase: Another Mode to Mimic 
Hypoxia  
2.1.1. Familial and Non-Familial Paragangliomas 
  A major breakthrough in answering the question, whether 
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in intermediate and energy metabolism, can be the primary 
cause of human tumors that was achieved in the year 2000 
by Baysal and colleagues [28]. The authors analyzed the 
genetic basis of a relatively rare and benign inherited human 
tumor disease, the hereditary paraganglioma (PGL), for 
which at least three gene loci (PGL-1, -2, -3) had been sus-
pected. Although this tumor can occur at various body sites, 
it is observed most often in the carotid body (CB), a tissue 
representing the major oxygen sensor in mammals. The CB 
stimulates the cardiopulmonary system under hypoxic condi-
tions [29] by processes, which are thought to be governed at 
the cellular level by HIF-1 [29-31]. Chronic hypoxia, e.g. 
caused by dwelling in high altitudes or some cardiopulmon-
ary disorders, induces cellular hyperplasia or anaplasia in the 
CB tissue [32-38]. Similar histologic changes observed in 
PGL [37, 39] first hint that some kind of HIF-1 mediated 
pseudo-hypoxia response may underlie PGL pathogenesis. 
This led to the hypothesis that the genetic defect in PGL may 
inactivate an essential component of the oxygen sensing ma-
chinery itself or of the signal transducing mechanisms on the 
way to HIF-1.  
  The genetic analysis of PGL-1 families [28] led to the 
discovery that the SDHD gene, encoding the small cyto-
chrome b subunit within the mitochondrial succinate dehy-
drogenase complex (SDH) is responsible for PGL-1. Germ-
line missense or nonsense mutations in this gene were de-
tected together with LOH of the second allele in the tumor 
tissue. The SDHD-gene, thus, behaved like a typical tumor 
suppressor, since biallelic loss was necessary for tumor de-
velopment. Later, it was, however, found that LOH not al-
ways occurred in the tumor tissue but some what mysteri-
ously remained the feature of maternal imprinting, i.e. the 
transmission of a diseased phenotype solely through the fa-
thers. The authors suggested that maternal imprinting may be 
related to the fact that in several PLG-1 families chromoso-
mal losses (LOH) of the SDHD region in the tumor tissue 
occurred selectively in the maternal chromosome, but the 
reason for this remained unknown.  
  This work demonstrated for the first time that mutations 
of enzymes of the oxidative mitochondrial metabolism can 
be tumorigenic. At this point, it was not clear as to how SDH 
dysfunction initiates tumor growth in the CB. SDH has a 
dual function in mitochondria, since it is an enzyme involved 
in the Krebs cycle and is part of the mitochondrial electron 
transport chain (ETC), where it is designated as ‘ETC com-
plex II’. This means that SDH participates in the intermedi-
ary metabolism, as well as in the production of reduced fla-
vin nucleotides, which support the electron flow, used for 
mitochondrial ATP synthesis. At first sight, it was not obvi-
ous as to how an inhibition of one of these two functions 
may lead to a pseudo-hypoxia response with HIF-1 activa-
tion, hyperplasia, anaplasia and at least development of a 
benign tumor. Meanwhile, a hypothesis has been deduced 
from cell culture studies, which proposes loss of an enzy-
matic function required for HIF1-degradation as the key 
mediator of SDH dysfunction, thus, connecting this novel 
tumor suppressor with the classical VHL gene (Fig. 1).  
 Studies  using  SDHA-mutant fibroblasts shed some light 
on the mechanism, although this subunit is currently not 
known to be prone to inactivating mutations in human tu-
mors, while two other subunits are involved in tumorigenesis 
(see below). In the mutant fibroblasts, SDH-deficiency was 
correlated with succinate accumulation and HIF-1 nuclear 
translocation [40]. The latter process was not observed in 
ATPase-deficient fibroblasts or under cell culture conditions 
with enhanced production of reactive oxygen species (ROS). 
These results suggested that the accumulation of the SDH 
substrate succinate in the Krebs cycle may be a better candi-
date as a starting point of enhanced HIF-1 signaling than a 
decrease in mitochondrial ATP or an increase in ROS pro-
duction by the defective enzyme.  
  Since succinate is a reaction product of the prolyl hy-
droxylase (PHD), which prepares HIF-1 to subsequent deg-
radation, it was suggested, that product-inhibition of PHD 
may play the key role. This view was strongly supported by 
the fact that the PHD substrate, -ketoglutarate (KG), inhib-
ited HIF-1 activation in the mutant fibroblasts. The prod-
uct/substrate equilibrium of PHD may be critically shifted 
also by tumorigenic SDH mutations. This may apply at least 
to some critical mutations of SDHB (see below), a subunit 
which together with SDHA forms the catalytic core, the in-
activation of which should lead to succinate accumulation. In 
other subunits and probably depending on the location of the 
affected codons, enhanced ROS production may however be 
essential [41, 42].  
  In the same year, when Baysal and colleagues had pub-
lished their work, the SDHC gene was identified as a second 
PGL locus. Germline mutations caused autosomal dominant 
paraganglioma type 3 (PGL-3), a form without genetic im-
printing [43]. Shortly thereafter mutations of SDHB and of 
SDHC / SDHD, which anchor the catalytic core to the inner 
mitochondrial membrane, had been identified as a frequent 
cause of all three familial PGL-types and as a less frequent 
cause of non-familial cases [44].  
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Model derived from cell culture studies to explain the 
‘pseudohypoxia effect’ of succinate dehydrogenase (SDH) inactiva-
tion, which may simply inhibit prolyl hydroxylase (PHD) by succi-
nate accumulation. PHD is required to prepare HIF1 to subsequent 
ubiquitin ligation and degradation. Inactivation of the well known 
Van-Hippel-Lindau tumor suppressor gene (VHL) directly destroys 
ubiquitin ligase activity.  
2.1.2. Pheocromocytoma and Other Tumors  
  Pheochromocytoma, a tumor of the adrenal medulla, 
which may cause secondary hypertension, occurs as a famil-
ial disease in about 10% of cases. These cases can be caused 284    Current Genomics, 2009, Vol. 10, No. 4  E. Kirches 
by germline mutations of various tumor suppressor genes, 
VHL being among them. This suggested that altered HIF-1 
signaling may play a role in patients with familial pheo-
chromocytoma. SDHB mutations were found in two of the 
five families screened and the same gene was occasionally 
affected in sporadic forms of the disease [45].  
 Familial  renal cell carcinomas (RCC) are also among 
those tumor types, which are sometimes associated with 
VHL-inactivation. SDHB mutations were not only detected 
in patients suffering from a familial tumor syndrome with 
early onset RCC and/or PGL [46], but were found also in 
4.4% of sporadic RCC cases [47]. Moreover, SDH germline 
mutations were observed in 13.5% of patients with Cow-
den’s syndrome without mutations in the tumor suppressor 
PTEN, which explains this rare, inherited hamartoma and 
tumor disease in more than 80% of cases [48].  
2.2. Fumarate Hydratase 
 Fumarate  hydratase  (FH) deficiency is an encephalopa-
thy inherited as an autosomal recessive trait, and is associ-
ated with mostly carboxyterminal germline mutations in the 
FH gene behind codon 250 [49-52]. Germline mutations 
clustering in the aminoterminal region before codon 250 
were however more recently associated with an autosomal 
dominant tumor syndrome causing uterine and skin leimyo- 
mata, as well as papillary renal cell cancer [53]. In 84% of 
the cases, the second allele was inactivated by LOH and the 
FH gene, therefore, behaved as a classical tumor suppressor. 
The tumor suppressor concept was further underlined by the 
observation, that the leiomyomata showed virtually no FH 
enzyme activity. Occasionally, mutations and/or LOH in the 
chromosomal region, which contains the FH gene, were also 
observed in non-syndromeuous leiomyomata [54]. FH is an 
enzyme placed in the Krebs cycle immediately behind SDH, 
suggesting that tumor development may involve similar 
mechanisms including an important role for succinate accu-
mulation.  
3. OTHER NUCLEAR-ENCODED MITOCHONDRIAL 
PROTEINS DISCUSSED IN CANCER 
3.1. Does Frataxin Play an Inhibiting Role in ROS-
Mediated Tumorigenesis ? 
  Friedreich’s ataxia is a severe neurodegenerative disease 
of adulthood, often accompanied by cardial hypertrophy and 
usually leading to the patient’s death within 15 years. It is 
inherited as a recessive autosomal trait, caused by an intronic 
GAA trinucleotid expansion in the frataxin gene, which 
switches off transcription of the affected allele [55]. Frataxin 
is a mitochondrial protein, which is suggested to be involved 
in iron homeostasis in the mitochondria, since a reduced 
amount of the protein in patients with the intragenic trinu- 
cleotide expansion leads to intramitochondrial iron deposits. 
Although the details of frataxin function are currently a mat-
ter of debate, these deposits may indicate an insufficient 
transport of iron to the sites of iron-sulfur cluster biogenesis 
by frataxin [56-59], which in turn may hamper the incorpora-
tion of correctly iron-loaded Fe/S-clusters into various mito-
chondrial proteins, such as the Fe/S-containing ETC com-
plexes. In cell cultures, frataxin inactivation was shown to 
result in ETC inhibition, as demonstrated by a diminished 
mitochondrial membrane potential, decreased O2-consump- 
tion and decreased oxidative ATP synthesis. Frataxin dys-
function may lead to an inhibition of mitochondrial energy 
metabolism. On the other hand, a dysfunction of ETC com-
plexes, as well as deposits of free iron (by Fenton reaction) 
can cause enhanced generation of ROS in the mitochondrial 
matrix and in the intermembrane space. Oxidative stress is 
thought to further damage ETC complexes and other redox-
sensitive proteins, such as the Krebs cycle enzyme aconitase. 
This oxidative stress component may further inhibit interme-
diary metabolism and oxidative ATP synthesis.  
  Ristow and colleagues analyzed for the first time a poten-
tial tumor suppressing function of frataxin in cell culture and 
animal models, although patients suffering from Friedreich’s 
ataxia are in no way prone to a higher tumor burden. The 
idea behind this work was a potential connection between 
the antioxidative properties of frataxin and ROS-mediated 
tumorigenesis. The authors analyzed this topic initially in 
murine 3T3L1 cells, which had been transfected with either a 
vector expressing human frataxin or a control construct [60]. 
Both cell clones were exposed to culture conditions with 
artificially enhanced ROS production. The cells overexpress-
ing frataxin exhibited a significantly lower number of an-
chorage-independent foci in the culture dishes and the rate of 
colony formation in soft agar assays was significantly lower, 
indicating that frataxin protected the cells from ROS-induced 
transformation into a tumor phenotype. This was further 
supported by the observation that only cells from the anchor-
age-independent foci were able to induce tumor growth 
when xenografted to nude mice.  
  While oxidative stress in frataxin-deficient patients with 
Friedreich’s ataxia may be due to the disturbed synthesis of 
Fe/S-clusters and mitochondrial iron deposits, it is less obvi-
ous as to how enforced overexpression of frataxin in normal 
cells may protect them against ROS. The authors explained 
the protective effect by the observed increase in glutathione 
peroxidase (GPx) activity and in reduced thiols. GPx and the 
reduced form of glutathione play an important role in the 
detoxification of H2O2, which is built as a product of the 
SOD-  (superoxide dismutase)  reaction.  Superoxide dismu-
tase 2 (SOD2) is a mitochondrial enzyme, which detoxifies 
superoxide radicals, released mainly from ETC complexes I 
and III into the mitochondrial matrix.  
  In a next step, the authors investigated the potential tu-
mor suppressing effect of enforced frataxin expression in the 
colon cancer lines MIP101, DLD2 and HT29, which lack 
endogenous expression of the protein. Mitochondrial oxida-
tive metabolism was enhanced in the transfected cells, as 
could be shown by an increase of mitochondrial membrane 
potential, cellular respiration and ATP content, as well as 
aconitase activity. Increased aconitase activity may be ex-
plained in part by decreased oxidative stress. Again, the fra-
taxin cells exhibited a lower colony formation rate in soft 
agar essays and a lower rate of tumor growth after xenotrans- 
plantation to nude mice [61]. The most direct evidence for a 
role of frataxin in carcinogenesis was reported by the same 
group using targeted hepatic disruption of frataxin expres-
sion in mice. The animals had reduced life spans and devel-
oped multiple hepatic tumors, in which high apoptotic and 
mitotic (Ki-67) indices were observed [62]. The liver speci-
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substances  (TBARS), a marker of lipid peroxidation, and 
elevated levels of oxidized glutathione, a classical oxidative 
stress marker. Activities of those mitochondrial enzymes, 
which contain Fe/S-moieties, i.e. aconitase and ETC com-
plexes I, II, III, were reduced. In accordance with an inhib-
ited oxidative metabolism, the ATP content of livers from 
knock-out animals was decreased.  
  The authors did not develop a detailed hypothesis regard-
ing the mechanism of liver tumorigenesis, but speculated 
that an observed reduction in p38-MAP-kinase phosphoryla-
tion may play a role, since activation of this type of mitogen 
activated protein kinase had been discussed earlier as a fac-
tor suppressing the formation of hepatic tumors [63, 64]. 
Although the authors did not discuss this issue, it might be 
speculated, whether the observed inhibition of SDH (com-
plex II) may participate in tumorigenesis.  
3.2. Other Genes Related to Oxidative Stress  
  SOD2 is the main enzyme to detoxify the superoxide 
generated by the ETC. Since probably all of the superoxide 
generated by ETC complex I and a part of that produced by 
complex III is released into the mitochondrial matrix, SOD2 
is located in this compartment. Import of the monomeric 
precursor protein requires a translocation through both mito-
chondrial membranes, mediated by the translocators of the 
outer (TOM) and inner membrane (TIM), for which a mito-
chondrial targeting sequence at the aminoterminus is needed. 
A Val/Ala polymorphism in codon 16 of this leader peptide 
is known, which predicts a profound conformational change 
between -helix and ß-sheet. Ala-16 homozygosity has been 
shown to be associated with poorer transport efficiacy, lead-
ing to a dicreased intramitochondrial formation of the homo-
tetrameric mature enzyme, which in turn reduces the antioxi-
dative capacity of mitochondria due to a lower enzyme activ-
ity [65]. The lowered SOD2 activity may usually be without 
major consequences for the cell, but may lead to oxidative 
stress, when other antioxidative mechanisms are disturbed at 
the same time. Li and colleagues observed that low blood 
selenium levels enhance the prostate cancer risk in individu-
als homozygous for the Ala-16 leader sequence [66]. This 
observation may be interpreted in terms of a synergism be-
tween decreased SOD2-activity and lowered activity of glu-
tathione peroxidase (GPx), a selenium-dependent enzyme.  
  Selenoprotein P is the most important selenium binding 
protein, which accounts for at least 40% of total plasma se-
lenium load [67]. The protein contains a polymorphism in 
codon 234, the alanine allele being associated with lower 
plasma selenium concentrations in men, which affect GPx 
activity [68]. It was therefore a logical step to investigate a 
possible synergism between Ala234 and the SOD2-leader 
polymorphism. Indeed, synergistic effects were observed, 
since men homozygous for the ‘wrong allele’ of both genes 
had a significantly enhanced risk of prostate cancer (odds 
ratio (OR) 1.43) or clinically aggressive prostate cancer (OR 
1.60). The OR became even more pronounced in men, who 
were strong smokers [69].  
3.3. Mutations Causing ETC Defects by Generating a 
Fragile Mitochondrial Genome 
  The precursors of most mitochondrial proteins are en-
coded by nuclear genes, translated into polypeptides at cyto-
plasmic ribosomes and imported into the mitochondria, to 
which they are targeted by mitochondrial leader sequences at 
their amino terminus. This rule applies also to the vast ma-
jority of polypeptides, which constitute the five OXPHOS 
complexes of the inner mitochondrial membrane, i.e. ETC 
complexes I to IV and the ATP-synthetase (F0/F1-ATPase, 
complex V). However, with the exception of complex II 
(succinate dehydrogenase), all OXPHOS complexes contain 
at least one polypeptide, which is encoded in a small (16.6 
kb) circular and intron-free DNA molecule in the mitochon-
drial matrix space, the mtDNA. Altogether the mtDNA en-
codes 13 OXPHOS polypeptides, as well as 2 ribosomal and 
22 tRNAs needed for their translation by ribosomes of the 
mitochondrial matrix.  
 DNA  polymerase   (POLG) is the enzyme, which repli-
cates this mitochondrial genome. It is necessary to maintain 
a functional ETC and OXPHOS. Interestingly, heterozy-
geous missense-, nonsense- or frameshift-mutations in the 
POLG gene do usually not cause a depletion of mtDNA, but 
lead to a fragility of the mitochondrial genome, which is 
prone to multiple large scale deletions in a proportion of 
mtDNA molecules, which can be detected in Southern blots 
of skeletal muscle DNA. These deletions usually affect some 
mtDNA-encoded tRNA genes besides protein-coding se-
quences and can inhibit ETC complexes I, III, and IV, as 
well as the ATP synthetase. The functional defect is trans-
lated into a phenotype, which predominantly affects skeletal 
muscles (muscle weakness and external ophthalmoplegia) 
and is usually transmitted as an autosomal dominant trait, 
designated adPEO (autosomal dominant progressive exter-
nal ophthalmoplegia) [70].  
  The POLG gene contains a polymorphic CAG repeat [71, 
72], which is conserved in all species investigated so far. 
Since the clearly dominating repeat length in the human 
population is 10, selective pressure seems to occur to con-
serve this length [73]. Men with homozygous deviations 
from this dominating repeat length were recently shown to 
have an increased risk of developing testicular germ cell 
cancer, mainly seminomas [74]. No correlation of repeat 
length with other clinico-pathological features was observed. 
Although the fraction of persons with a homozygous ‘non-
10’ allele was significantly higher among cancer patients 
(4,9%) as compared to the general population (1.3%), the 
generally low frequency shows that the aberrant repeat 
length can be viewed only as mild risk factor for tumor de-
velopment. 
4. ROLE OF MTDNA-ENCODED MITOCHONDRIAL 
PROTEINS IN CANCER 
4.1. ATPAse Mutation Enhancing Tumorigenicity of 
Prostate Cancer Cells in Nude Mice 
  Since more than ten years, a growing number of articles 
described somatic mutations of the mitochondrial genome 
(mtDNA) in human tumors, by comparing tumor and adja-
cent normal tissue or blood usually with sequencing tech-
niques. Sometimes more sophisticated techniques were used, 
dedicated to the detection of a low burden of mutated 
mtDNA (heteroplasmy). Often these mutations occurred in 
the non-coding, so called D-loop region, or were silent base 
substitutions. Usually, these base exchanges did not include 286    Current Genomics, 2009, Vol. 10, No. 4  E. Kirches 
pathogenic mutations known from ‘mitochondrial disorders’ 
and could not be predicted to have functional consequences 
by other criteria, such as introduction of stop-codons, frame-
shifts or alteration of conserved tRNA loop-structures. A 
large proportion of these mutations actually corresponded to 
known human polymorphisms. They could be suspected to 
be caused by oxidative stress and to be enriched in the tumor 
tissue as a consequence of the clonal expansion of a single 
somatic cell.  
  In the year 2005, however, Petros and colleagues demon-
strated a direct causal connection between a known patho-
genic mtDNA mutation (T8993G in the ATPase-6 gene) and 
the tumorigenecity of PC3 prostate cancer cells in nude mice 
[75]. This mutation was well known to elicit mitochondrial 
disorders. It can be responsible either for a severe CNS dis-
ease leading to symmetrical necroses in the brain and early 
death (Leigh syndrome) or to the less severe disease NARP 
(neuropathy, ataxia and retinitis pigmentosa), which seems 
to depend on the exact proportion of mutant and normal 
DNA in the CNS. Generally, very high burdens of the muta-
tion (> 95% of total mtDNA in the relevant tissues) are 
thought to be necessary to cause any mitochondrial disorder. 
This suggests that the ATP synthetase function is signifi-
cantly hampered only by extremely high mutation loads, but 
even lower percentages of mutant DNA may cause enhanced 
ROS production. Petros and colleagues detected this trans-
version as a heteroplasmic germline mutation in a patient 
with prostate cancer. The authors introduced mtDNA carry-
ing the mutation and in parallel unaffected mtDNA from the 
same patient into mtDNA-depleted PC3 prostate cancer 
cells, using the cybrid technique [76]. The PC3 cells with the 
mitochondrial genotype 8993G developed tumors with a 
significantly enhanced growth rate in nude mice, as com-
pared to the wild-type. Effects of other variations in the mi-
tochondrial or nuclear genomes were excluded by this so-
phisticated approach. The mitochondrial haplogroup, as well 
as other mtDNA positions potentially influencing OXPHOS 
were identical in both xenografted tumor cell lines (genotype 
of the patient). The nuclear background was that one of PC3 
tumor cells in both cases. Therefore, the growth difference 
between the two manipulated tumor cell clones (‘transmito-
chondrial cybrids’) could be attributed to the T8993G muta-
tion. Although unproven in their article, the authors dis-
cussed a probable role of enhanced mitochondrial ROS pro-
duction by the mutant cells to support tumor growth, since 
ROS are known to influence transcription factors [77], signal 
transducing kinases and regulatory phosphatases and angio-
genic factors. The ATP synthetase mutation T8993G is 
known to induce enhanced ROS production in other cell 
types, including cybrids based on the osteosarkoma cell line 
143B. Increased, but still moderate levels of mitochondrial 
ROS production may be the cause of enhanced tumori-
genecity, as suggested by the authors.  
4.2. Spectrum of Human Tumor Diseases, in which 
mtDNA Mutations were Observed 
  Despite Warburg’s early suggestion of a causal role of 
OXPHOS defects in cancer development [1, 2], the mito-
chondrial genome of cancer cells had not been studied until 
1998, when Polyak and colleagues sequenced the mtDNA of 
ten human colorectal cancer cell lines [78]. The authors de-
tected 12 mutations in 7 of the cell lines (70%). Most base 
exchanges occurred in rRNA genes or were missense muta-
tions, only two were functional without any doubt (frame 
shift and chain termination). Although tumor cells often con-
tain a relatively small number of mitochondria with a few 
mtDNA molecules per mitochondrion, the resulting number 
of mtDNA copies per cell still guarantees, that a new so-
matic mtDNA mutation initially represents only a minor 
fraction of total tumor mtDNA, a state called heteroplasmy. 
Having this situation in mind, it was rather surprising that 
most of the mutations were found to be homoplasmic, at 
least at the sensitivity level of DNA sequencing. Homoplas-
mic mtDNA mutations were later often observed in human 
tumor tissues by other authors and do not represent a rare 
event or a special feature of long cultivated cell lines. As an 
obvious explanation for homoplasmy, Polyak and colleagues 
suggested that the mutated mtDNA was dominant at the in-
tracellular and intercellular level in the tumors, from which 
the cell lines had been derived. This was an important sug-
gestion, since it implied that at least one of the observed mu-
tations per mitochondrial genome should have conferred a 
selective advantage and, thus, be ‘functional’. This hypothe-
sis would suggest a role of mtDNA mutations to promote the 
proliferation of certain types of tumor cells just in the sense 
of Warburg’s hypothesis. However, selective pressure is not 
the only explanation for homoplasmy, and not even the sim-
plest one, as will be outlined below (see section 4.3).  
  In the same year, Habano and colleagues analyzed 45 
colorectal tumor samples for ‘microsatellite instability’ 
within some homopolymeric sequence tracts of mtDNA [79]. 
The term ‘microsatellite instability’ was misleading in a 
double sense. These sequence tracts do not fullfill the defini-
tion of microsatellites. In addition, the low mismatch repair 
activity in mitochondria is not the only explanation for their 
length variability in human tumors, as discussed below (see 
section 4.3). The term was probably coined to remind nu-
clear microsatellite instability due to mismatch repair defects 
in inherited non-polyposis colorectal cancers. The authors 
detected length changes of the polycytosine tract of the hy-
pervariable region 2 (HVR2) of the mitochondrial D-loop in 
20 tumors (44%). This sequence tract, often referred to as 
D310 in the tumor literature, is meanwhile known to be 
highly variable in several solid tumor types [80]. It is non-
coding (like the whole D-loop) and two different length vari-
ants are known to be the dominating constitutive genotypes 
in normal human tissues, often in a heteroplasmic mixture. 
Nevertheless, the tract is essential for binding and correct 
nuclease processing of a RNA primer, which is required for 
mtDNA replication. In tumors, rare length variants are more 
frequently observed and even rather long tracts occur, which 
are never seen as constitutive genotypes in blood samples. In 
the cancer samples originally analyzed by Habano and col-
leagues, the authors later described some complex I muta-
tions in 16% of cases in a more detailed analysis [81].  
 Parrella  et al. [82] investigated 18 primary breast cancers 
(invasive ductal carcinomas) from 17 women by direct se-
quencing. MtDNA mutations were detected in 11 tumors 
(61%), 42% being length alterations in D310. The remaining 
were base substitutions in several protein-coding genes. Mu-
tations in the coding and non-coding regions of the mito-
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head and neck cancers [83, 84], in 64% of bladder and 43% 
of lung cancer patients [84]. Among patients with multicen-
tric hepatocellular carcinoma, 68% exhibited mtDNA muta-
tions at least in one of the tumors, including a high frequency 
of D310 length variations (62% of patients).  
  We and other authors detected a high frequency of D-
loop mutations in astrocytic brain tumors [85-87]. We ap-
plied D310 length variation to verify clonality in gliomatosis 
cerebri, an astrocytic tumor disease, in which several brain 
lobes are diffusely infiltrated without clearly visible tumor 
margins [88]. The loss of a heteroplasmic D310 genotype in 
one hemisphere affected by gliomatosis corresponded with a 
p53 mutation in this hemisphere, thus, verifying the clonal 
expansion of the altered mitochondrial genotype during tu-
mor growth. By screening the mitochondrial genome with 
time consuming temperature gradient gel electrophoresis, 
followed by sequencing, mutations were identified in 40% of 
medulloblastomas, the most frequent brain tumor of child-
hood [89].  
  Studies focusing on the highly susceptible D-loop region 
or sequencing a few mitochondrial genes in addition, tended 
to find a lower proportion of tumors, harboring a base ex-
change or insertions/deletions as compared to studies, which 
tried to assess the mitochondrial genome as much as possi-
ble. A recent chip analysis of 94% of the mitochondrial ge-
nome in 15 pancreatic cancers detected at least one somatic 
mutation in every tumor, suggesting that indeed most solid 
tumors contain mtDNA mutations.  
4.3. Is There any Benefit for the Tumors? Positive Selec-
tion Versus Random Drift  
  Even polymorphisms of the mtDNA observed in healthy 
mammals are not necessarily neutral, e.g. during the devel-
opment and aging of organs. This aspect of mitochondrial 
genetics had already been illuminated in a study creating 
heteroplasmic mice by genetic engineering [90] in the year 
1997. The mitochondrial genome of two normal healthy 
mouse strains had been mixed to achieve a balanced artificial 
heteroplasmy. The two genomes could easily be distin-
guished by means of PCR. The authors even analyzed het-
eroplasmic mice with two different nuclear genomes to ex-
clude a potential role of nuclear background. The unexpected 
result of that study was a tissue-specific up- or downregula-
tion of one of the two mitochondrial genomes during devel-
opment and adult life of the mice. This result demonstrated 
that even mitochondrial genomes, which do not carry any 
known functional mutation, can differ in their replicative 
fitness in different organs of mammals.  
  Originally, the surprising observation of homoplasmy for 
a significant proportion of somatic mtDNA mutations in hu-
man tumor cells was also interpreted as a replicative advan-
tage of mutated mtDNA and/or a growth or survival advan-
tage for the cells carrying the affected mitochondria [78, 84, 
91]. Having in mind the above cited results in heteroplasmic 
mice, even a proportion of the D-loop, rRNA, tRNA or mis-
sense mutations in non-conserved codons may be interpreted 
to confer a ‘selective advantage’.  
  However, it is not possible to draw this conclusion sim-
ply from the observed frequency of homoplasmic tumors, as 
could be demonstrated by computer modeling. Coller and 
colleagues [92] have shown that a sufficient random drift of 
heteroplasmic mtDNAs theoretically occurs even under con-
ditions of unbiased mtDNA replication and sorting during 
cell divisions, which can explain the observed frequency of 
homoplasmy. The computer models were based on some 
assumptions regarding mtDNA content, mutation rate and 
number of cell divisions minimally required to generate a 
detectable solid tumor, which can not be proven in detail. 
However, even rather conservative estimations of these pa-
rameters yielded results, which were in good accordance 
with the observed rate of homoplasmy. This study forced 
investigators to accept the notion that homoplasmy of a tu-
mor mutation is no proof of functional relevance. It seems, 
thus, likely that a large proportion of all observed mutations 
are nothing else but indicators of a clonal cell expansion, 
which may however be exploited as a tool of early cancer 
detection anyway.  
  Some sentences may still be dedicated to the usage of the 
word ‘somatic mutation’ in the tumor literature, which im-
plies that in all cases a base exchange or deletion/insertion 
occurred de novo in a tumor cell or precursor cell. This as-
sumption seems questionable, at least for some nucleotide 
positions of mtDNA, which are often heteroplasmic in nor-
mal human tissues. The poly-cytosine tract D310, a so called 
‘hot spot of somatic mutations’ in solid tumors, is a good 
example. The tract occurs in the blood of roughly half of all 
healthy individuals in one of the two variants C7TC6 or 
C8TC6, as determined by sequencing. Especially individuals 
with the longer tract are usually heteroplasmic, i.e. the lym-
phocytes (and other tissues) contain lower amounts of the 
shorter variant, as detected by PCR techniques. Even other 
variants of the tract can occur in normal tissues. It seems, 
thus, reasonable to assume that length alterations of this 
polycytosine stretch in solid tumors, observed during se-
quencing, are often caused simply by relative shifts between 
two or more pre-existing heteroplasmic genotypes of the 
precursor cell. In our laboratory, mtDNA from some 
glioblastomas had been cloned for extensive analysis of low 
abundant mtDNA mutations. The ‘constitutive genotype’ of 
one patient in this study (normal brain tissue) consisted of 
two mitochondrial genomes, which could be distinguished 
by D310 length and two D-loop transitions. One of these 
genomes was clearly lost in the glioblastoma [85]. This 
change was attributed to heteroplasmic drift, since three in-
dependent events would have been necessary to explain this 
result by somatic mutations. Unless investigated by specific 
PCR-assays for a given nucleotide position, one can never be 
sure that adjacent normal tissue did not contain low amounts 
of the mtDNA observed as the dominant genotype in a tu-
mor. However, the exact nature of the observed sequence 
alterations in human tumors plays no role for their potential 
use in cancer detection, as long as they represent clonal cell 
expansions. In the following sections, the term ‘mutation’ 
will be used regardless of the problems associated with it 
especially regarding D310.  
4.4. Are mtDNA Mutations Associated with Patient Sur-
vival? 
  At least two studies reported preliminary data, suggesting 
that mutated mtDNA is a marker of poor survival in ad-
vanced cancer patients. In a large series of 202 patients suf-288    Current Genomics, 2009, Vol. 10, No. 4  E. Kirches 
fering from NSCLC (non small cell lung cancer) of various 
histological subtypes, mitochondrial rRNA genes and D-loop 
were analyzed. Mutations were found only in the latter re-
gion in 34.7 % of cases [93]. No significant differences in 
mutation frequency occurred between the histological sub-
types (adenocarcinoma, squamous cell carcinoma, bron-
choalveolar carcinoma, large cell carcinoma), but mutations 
accumulated significantly in tumor grades IIIb or higher 
(p<0.0001). Tumor grades had been determined according to 
the international staging system [94]. The most important 
result of that study was the significantly decreased survival 
of advanced cancer patients harboring mtDNA mutations. 
This difference was observed within grade IIIb and within 
grade IV (Fig. 2). Although a prospective study (fresh mate-
rial collected prior to cancer treatment), the article did not 
contain any information regarding chemo- and radiotherapy.  
  Lievre and colleagues [95] retrospectively analyzed the 
D-loop region of 365 colorectal cancer patients from the 
Digestive Cancer Registry of Cote d’Or (France). Mutations 
were detected in 38.3% of the samples. The 3-year survival 
rate of these patients was 53.5% as compared to 62.1% in the 
negative cases (p = 0.05). The benefit of a non-mutated 
status became more pronounced in advanced cancers (Fig. 
3). If all stage III cases were included, the 3-year survival 
rates of the groups with and without mutation were 47.4% 
versus 70.0%, respectively (p<0.02). If fluorouracil had been 
used as adjuvant chemotherapy, the difference was even 
more pronounced, i.e. 45.4% vs. 78.3% (p<0.02).  
  Although the results of both studies suggest mtDNA as 
an additional prognostic marker to refine histology-based 
prognoses, the suitability of such approaches remains ques-
tionable, unless the treatment regimens (chemotherapy and 
radiation) are more precisely reported and controlled in such 
analyses. This is not a simple issue in retrospective studies, 
but could be done by collecting mtDNA from patients, who 
are dedicated to participate in controlled clinical trials per-
formed for testing new therapy regimens.  
5. mtDNA AS A POTENTIAL TOOL OF EARLY 
CANCER DETECTION  
5.1. Are mtDNA Mutations Suitable for Early Cancer 
Detection? 
  Although the frequency of mtDNA mutations in solid 
human tumors is still a matter of debate with sometimes 
large differences occurring between studies, several studies 
suggested that D310 length variation and base substitutions 
in the whole mitochondrial genome are often already detect-
able in a premalignant stage. In patients with a clinically 
manifested cancer, these mtDNA alterations can often be 
detected in paired bodily fluids, probably allowing the de-
velopment of non-invasive diagnostic assays. Bodily fluids 
have been analyzed for the first time ten years ago by Fliss 
and colleagues in cancers of head and neck (n = 13), bladder 
(n = 14) and lung (n = 14) [84]. In patients harboring mu-
tated mtDNA, in their bladder carcinoma, sequence variants 
were generally detectable in the paired urine samples. Most 
paired saliva samples of head and neck cancers were infor-
mative too, while the analysis of bronchoalveolar lavage 
(BAL) of lung cancers was difficult due to the dilution of 
tumor cell DNA in the relatively large amounts of BAL-
fluid. Highly sensitive oligonucleotide mismatch ligation 
assays, created to specifically amplify a single base ex-
change, were successful in two cases, thus, delivering at least 
the proof of principle. Since mtDNA usually exhibits a much 
higher copy number per cell as compared to nuclear single 
copy genes, this abundance may facilitate PCR-detection in 
diluted samples. This is well known to the forensic commu-
nity, since mtDNA can sometimes be used to analyze DNA-
traces, for which commonly used markers fail. In the bodily 
fluids of cancer patients, a second problem occurs, i.e. the 
admixture of tumor cell DNA with DNA of normal epithelial 
cells, which may also be released into the fluids analyzed. 
This may be regarded as a severe problem, since it hampers 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparison of the cumulative survival rates between 
NSCLC patients with and without mitochondrial DNA mutations 
(modified according to [93]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Comparison of cumulative survival rates in patients with 
stage III colorectal cancer with and without D-loop mutations, ei-
ther receiving fluorouracil-based adjuvant chemotherapy (A) or 
receiving no adjuvant chemotherapy (B). Modified according to 
[95]. Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer  Current Genomics, 2009, Vol. 10, No. 4    289 
all sequencing strategies, including modern chip technolo-
gies (see below), which are not extremely sensitive in dis-
covering heteroplasmic base positions. 
  Fliss and colleagues, thus, measured the relative abun-
dance of mutated mtDNA as compared to mutated p53 nu-
clear DNA in two BAL samples and found the mtDNA se-
quence to be 19 and 220-fold more abundant. These results 
suggested that mtDNA may be a more sensitive tool for early 
cancer detection as compared with nuclear genes. Later, the 
same group identified mtDNA mutations of three prostate 
cancer patients in paired urine and, more surprisingly, 
plasma samles. In one case, the alteration was present in the 
corresponding PIN lesion (prostate intraepithelial neo-
plasm).  
  In a large series of 137 premalignant lesions of the head 
and neck from 93 patients, analyzed selectively for D310 
status, 22% of the benign hyperplasias, but 62% of 
squamous carcinomas in situ, harbored an altered length of 
the polycytosine tract [96]. The same marker was analyzed 
in ductal lavage (DL) of the breast in a small series of 14 
women with no clinical evidence of breast cancer [97]. Nine 
of the women were at high-risk of developing cancer, since 
they harbored germline mutations of the BRCA1 (breast can-
cer  1) gene, while five women were known to be non-
carriers. Only three (30%) of the carriers exhibited detectable 
length alterations of D310 in DL, which seems to occur in 
about 30% of breast cancer tissues [80].  
5.2. mitoChip-Technology 
  The small control-region of mtDNA replication and tran-
scription is usually designated in its total length as ‘D-loop’ 
in the tumor literature, although the term displacement loop 
(D-loop) originally characterized only a portion of the con-
trol region, able to built a loop structure by binding a short 
single-stranded primer, displacing the two strands of 
mtDNA. Although the control region seems to harbor the 
highest density of point mutations in human tumors, the ma-
jority of mutations may be missed be focusing on this region, 
which comprises only about 6.5% of total mtDNA. Since 
conventional capillary-sequencing of the complete mito-
chondrial genome (16.6 kb) is laborious and time consum-
ing, parallel sequencing strategies had to be developed. Hy-
bridization of fluorescent DNA samples to oligonucleotide 
arrays offers the opportunity to sequence the whole mito-
chondrial genome in a single hybridization experiment. Such 
arrays (MitoChip) have been constructed on the basis of the 
Custom Resequencing Microarray platform from Affymetrix 
(USA). The chip contains around 300.000 regions of ~500 
m
2 (features), each representing an oligonucleotide of 25 
bp. Each mtDNA position is represented by four features, 
which differ only by base #13, being one of the four DNA 
nucleotides. Fluorescent mtDNA samples, generated by 
long-PCR and fragmentation, will hybridize most efficiently 
to the feature representing an exact match, which will thus 
show the brightest fluorescence. The position of this feature 
is recognized by a microarray-scanner. This technique 
showed a nearly perfect reproducibility in repeated hybridi-
zations (>99.99%) and was able to detect mutations in six of 
the nine bodily fluid samples (urine, pancreatic juice) from 
patients with bladder cancer (n = 5) or pancreatic cancer (n = 
4) [98]. While the D-loop was omitted in the first generation 
chip due to high CG-content, this important region was in-
cluded in the second version (v2.0), which moreover con-
tained a redundant tiling for 500 of the most common haplo-
types [99]. Thus, MitoCHip (v2.0) allowed for the first time 
the examination of the whole mitochondrial genome in a 
single hybridization experiment. 
  Sui and colleagues [100] analyzed 14 precancerous le-
sions of the digestive tract, all of which were found to ex-
hibit at least one mutation. Seven of these samples had been 
obtained by endoscopic biopsies from Barrett esophagus, 
showing Barret mucose without concomitant dysplasia (n = 
2), low-grade dysplasia (n = 4) or high-grade-dysplasia (n 
=1), thus, demonstrating mtDNA alterations even in the ab-
sence of histopathologic evidence of dysplasia. The remain-
ing samples analyzed had been taken from four patients with 
colorectal adenomas (including one sessile serrated ade-
noma) and from three patients undergoing colectomy for 
long-standing idiopathic bowel disease with concomitant 
dysplasia. None of the analyzed adenomas had shown histo-
pathologic evidence of invasive adenocarcinoma.  
  The affected sites of mtDNA were distributed over the 
whole mitochondrial genome (Fig. 4), again demonstrating 
the necessity of a global approach. The majority of altera-
tions were heteroplasmic.  
 
 
 
 
 
 
 
Fig. (4). Distribution of mtDNA mutations ovserved with the MitoChip technology in preneoplastic lesions of the gastrointestinal tract 
(modified according to [100]). Abbreviations = mitochondrial genes according to international notation (see www.MITOMAP.com).  290    Current Genomics, 2009, Vol. 10, No. 4  E. Kirches 
  Still using the initial MitoChip version (v1.0), supple-
mented by capillary sequencing of the D-loop, Jakupciak et 
al. recently analyzed a series of early stage cancers, includ-
ing bladder (n = 3), kidney (n = 13) and lung (n = 8) and 
paired bodily fluids, urine or BAL respectively [101]. Muta-
tions of the mtDNA, heteroplasmic in most cases, were de-
tected in all three bladder cancers. They were found in 69% 
of kidney and 79% of lung cancers. The paired bodily fluids 
exhibited mutations, i.e. their genotype was distinct from the 
constitutive genotype in blood, in 36% of bodily fluid sam-
ples, including 43% of BAL samples.  
6. CONCLUDING REMARKS 
  Several mitochondrial and nuclear genes of mitochon-
drial components have been associated with cancer. At least 
for some nuclear genes, which code polypeptides of enzymes 
involved in the Krebs cycle, a relationship between gene 
mutation and cancer development in humans is clearly 
proven. These genes play a role mainly in rare inherited tu-
mors, but screening for somatic mutations is of interest in 
some sporadic tumor types too.  
  Despite their high frequency in most solid human tumor 
types investigated so far, a causal role for a significant por-
tion of mtDNA mutations in cancer cannot be claimed. Al-
though some mtDNA mutations may enhance tumor growth, 
the enrichment of mutated mtDNA in solid human tumors 
can be explained by random drift, without need of any selec-
tive advantage. Irrespective of their biological role, mtDNA 
mutations may be a tool for early cancer detection. Recent 
studies, using the MitoChip technology, suggest that hetero-
plasmic and homoplasmic base exchanges are detectable in 
the majority of solid human tumors, even in early tumor 
stages or precancerous lesions. Especially in tumors seeding 
cells into an easily accessable bodily fluid, the screening of 
such fluids may be a hopeful technique. The MitoChip tech-
nology has to be tested in larger series of early cancers to 
allow an estimation of its practical suitability. However, al-
ready at this point two major issues have to be discussed. 
  First of all, one has to evaluate, what is a meaningful 
definition of a ‘mutation’, indicative of cancer growth. It is 
likely that global sequencing approaches will sometimes 
detect sequence differences between bodily fluid and blood, 
which are not observed in the tumor tissue of the same pa-
tient, e.g. in the recent study of Jakupciak and colleagues, 
this situation occurred in five patients [101]. Several expla-
nations can be proposed, including oxidative stress in normal 
epithelial tissues, pre-existing tissue-specific heteroplasmy, 
or technical reasons. The observed discrepancies between 
tumor tissues and corresponding fluids imply that global 
mutation data must be interpreted with care. At least, it will 
be necessary to learn more about the frequency of mis-
matches between blood and bodily fluids in unselected indi-
viduals without known cancer, premalignant lesions or in-
flammatory disease in the organ of interest.  
  A second point requiring discussion is a technical one. 
As already stated by Sui et al. [100], it is important to stress 
that chip based chemistry is best suited for detection of sin-
gle base pair alterations, but it is likely that many inser-
tions/deletions, frameshift mutations, and large scale dele-
tions are missed by this technique. Generally, array technol-
ogy should be much less sensitive for detection of hetero-
plasmic mutations in a huge excess of wild-type mtDNA, 
e.g. one can speculate that early detection of recurrence of a 
bladder or colon carcinoma, which contains a previously 
sequenced point mutation (follow-up), should be more mean-
ingful by exploiting specific PCR-assays. However, if the 
goal is development of techniques for early detection of pre-
viously unknown cancers (screening), the whole mitochon-
drial genome must be analyzed. This can be done efficiently 
only by array technology, which has already delivered the 
proof of principal for this purpose. The development of this 
technology is, thus, connected with great expectations for the 
future. 
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